サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784799

トラコーマ治療の世界市場

Trachoma Treatment

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
トラコーマ治療の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トラコーマ治療の世界市場は2030年までに7億990万米ドルに達する見込み

2024年に5億3,470万米ドルと推定されるトラコーマ治療の世界市場は、2024～2030年の分析期間にCAGR 4.8%で成長し、2030年には7億990万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるマクロライドは、CAGR 3.8%を記録し、分析期間終了時には2億7,070万米ドルに達すると予想されています。テトラサイクリンセグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は1億4,570万米ドルと推定され、中国はCAGR 7.5％で成長すると予測される

米国のトラコーマ治療市場は、2024年に1億4,570万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.5%として、2030年までに1億3,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と4.8%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

トラコーマ治療市場の動向と促進要因のまとめ

トラコーマ治療は世界ヘルスへの取り組みと新規治療薬によってどのように進化しているか？

トラコーマは世界的に失明の主要な感染症であり、特に清潔な水や衛生設備へのアクセスが限られている低所得地域では、依然として公衆衛生上の大きな問題となっています。この病気はクラミジア・トラコマティスによって引き起こされ、複数の段階を経て進行し、治療しなければ瘢痕化し、視力喪失に至る。世界保健機関（WHO）や国際トラコーマ・イニシアティブなどの組織が主導するトラコーマ撲滅への世界の取り組みは、SAFE戦略（手術、抗生物質、顔の清潔さ、環境の改善）を通じて、治療へのアクセスを大幅に改善しました。アジスロマイシンの大量投与（MDA）は、感染率の低下と合併症の予防という画期的な効果をもたらしました。しかし、抗生物質耐性、再感染リスク、流行地域のヘルスケアインフラ不足といった課題は依然として残っています。世界保健機関が2030年の撲滅目標に向けて推進する中、治療薬、診断薬、公衆衛生介入における進歩は、トラコーマ管理をどのように改善するのでしょうか？

どのような技術革新がトラコーマ治療を前進させているのか？

トラコーマ治療における新たな開発は、抗生物質の投与方法の改善、手術成績の向上、ワクチンに基づく予防戦略の開発に重点を置いています。AIを活用した診断ツールは、早期の感染症の特定に役立ち、タイムリーな介入を可能にしています。アジスロマイシンの単回投与、長時間作用型製剤は、コンプライアンスと治療効果を改善するために研究されています。吸収性縫合糸やレーザーを用いた手技など、低侵襲の手術手技により、睫毛乱生症治療の合併症が減少しています。さらに、トラコーマに特異的なワクチンの研究が進行中であり、長期的な免疫を提供し、感染の連鎖を断ち切ることを目指しています。

なぜトラコーマ治療の需要が増加しているのか？

顧みられない熱帯病（NTDs）に対する世界の取り組みの高まり、国際保健機関からの資金提供の増加、抗生物質の流通網の改善が、トラコーマ治療の需要を促進しています。衛生教育プログラムの拡大は、疾病対策への取り組みをさらに後押ししています。さらに、モバイルヘルス（mヘルス）ソリューションの進歩は、より良い疾病監視を可能にし、遠隔地のコミュニティにおける支援活動を向上させています。

トラコーマ治療市場の成長を促進する要因は？

NTD撲滅のための世界の保健資金、抗生物質ベースの大量薬剤投与の採用増加、診断および手術技術の進歩、公衆衛生インフラの改善により、市場は拡大しています。流行地域のヘルスケアへのアクセスが改善されるにつれて、トラコーマ撲滅の取り組みが加速し、世界中で失明率が大幅に低下すると予想されます。

セグメント

薬剤クラス別（マクロライド系薬剤、テトラサイクリン系薬剤、眼科用抗感染症薬、スルホンアミド系薬剤）;投与経路別（経口剤、局所剤）

調査対象企業の例

  • AbbVie Inc.
  • Advancing Chemical Industries（ACI）
  • Apotex Inc.
  • Arbor Pharmaceuticals（Azurity Pharmaceuticals）
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.（Viatris）
  • Novartis AG
  • Pfizer Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33168

Global Trachoma Treatment Market to Reach US$709.9 Million by 2030

The global market for Trachoma Treatment estimated at US$534.7 Million in the year 2024, is expected to reach US$709.9 Million by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Macrolides, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$270.7 Million by the end of the analysis period. Growth in the Tetracycline segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.7 Million While China is Forecast to Grow at 7.5% CAGR

The Trachoma Treatment market in the U.S. is estimated at US$145.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$138.7 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Trachoma Treatment Market Trends & Drivers Summarized

How Is Trachoma Treatment Evolving with Global Health Initiatives and Novel Therapeutics?

Trachoma, the leading infectious cause of blindness worldwide, remains a major public health concern, particularly in low-income regions with limited access to clean water and sanitation. The disease, caused by Chlamydia trachomatis, progresses through multiple stages, leading to scarring and vision loss if untreated. The global effort to eliminate trachoma, led by organizations such as the World Health Organization (WHO) and the International Trachoma Initiative, has significantly improved treatment accessibility through the SAFE strategy-Surgery, Antibiotics, Facial cleanliness, and Environmental improvements. Azithromycin mass drug administration (MDA) has been a game-changer, reducing transmission rates and preventing complications. However, challenges such as antibiotic resistance, reinfection risks, and lack of healthcare infrastructure in endemic areas persist. As global health organizations push toward the 2030 elimination goal, how will advancements in therapeutics, diagnostics, and public health interventions further improve trachoma management?

What Technological Innovations Are Advancing Trachoma Treatment?

New developments in trachoma treatment focus on improving antibiotic delivery, enhancing surgical outcomes, and developing vaccine-based prevention strategies. AI-driven diagnostic tools are helping identify early-stage infections, ensuring timely intervention. Single-dose, long-acting azithromycin formulations are being explored to improve compliance and treatment efficacy. Minimally invasive surgical techniques, including absorbable sutures and laser-based procedures, are reducing complications in trichiasis correction. Additionally, ongoing research into trachoma-specific vaccines aims to provide long-term immunity and break the cycle of transmission.

Why Is the Demand for Trachoma Treatment Increasing?

The rising global commitment to neglected tropical diseases (NTDs), increasing funding from international health organizations, and improvements in antibiotic distribution networks are driving demand for trachoma treatment. The expansion of sanitation and hygiene education programs is further supporting disease control efforts. Additionally, advancements in mobile health (mHealth) solutions are enabling better disease surveillance, improving outreach in remote communities.

What Factors Are Driving the Growth of the Trachoma Treatment Market?

The market is expanding due to global health funding for NTD eradication, increasing adoption of antibiotic-based mass drug administration, advancements in diagnostic and surgical techniques, and improvements in public health infrastructure. As healthcare accessibility improves in endemic regions, trachoma elimination efforts are expected to accelerate, significantly reducing blindness rates worldwide.

SCOPE OF STUDY:

The report analyzes the Trachoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-Infective, Sulfonamides); Administration Route (Oral, Topical)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Advancing Chemical Industries (ACI)
  • Apotex Inc.
  • Arbor Pharmaceuticals (Azurity Pharmaceuticals)
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V. (Viatris)
  • Novartis AG
  • Pfizer Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Trachoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • WHO-Led Elimination Campaigns Spur Global Procurement and Distribution of Antibiotics
    • Increasing Deployment of Mass Drug Administration (MDA) in Endemic Regions Enhances Treatment Access
    • Advancements in Azithromycin Distribution Logistics Improve Supply Chain Resilience
    • Integration of Trachoma Programs With Broader NTD (Neglected Tropical Disease) Strategies Gains Momentum
    • Expansion of SAFE Strategy (Surgery, Antibiotics, Facial Cleanliness, Environmental Improvements) Enhances Impact
    • Partnerships Between Governments, NGOs, and Pharma Drive Resource Mobilization
    • Mobile Surgery Units and Training Programs Expand Access to Corrective Procedures
    • R&D in Resistance Monitoring and Dosing Protocols Strengthens Long-Term Efficacy
    • Improved Diagnostic Screening in School-Age Children Supports Early Detection and Treatment
    • Greater Involvement of Local Health Workers in Surveillance and Delivery Improves Community Engagement
    • Availability of Donor-Funded Antibiotics Reduces Cost Barriers in Low-Income Countries
    • Growing Integration With Eye Health and Vision Care Initiatives Broadens Treatment Reach
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Trachoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Trachoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ophthalmic Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ophthalmic Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ophthalmic Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sulfonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sulfonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Sulfonamides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • JAPAN
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • CHINA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • EUROPE
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Trachoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • FRANCE
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • GERMANY
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Trachoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • INDIA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Trachoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Trachoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • AFRICA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030

IV. COMPETITION